A Study of the Clinical Efficacy and Safety of 100% Cassia Alata Extract Against Tinea Versicolor

Sponsor
The University of The West Indies (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05730244
Collaborator
(none)
60
1
2
16.5
3.6

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare the effects of Cassia alata extract in treating tinea versicolor (ring worm skin condition) to placebo consisting of alcohol, green food colouring and glycerin in adult Jamaicans ages 18 to 89 years. The main questions the study aims to answer are:• Does the use of this extract heal the kills the ring worm fungus and clears up the rash faster compared to placebo • Does the use of this extract have significant side effects ie Is it safe compared to placebo. Participants will be asked to apply a small portion about 1 ml of the extract or placebo to the skin rash twice daily at least 8 hours and attend dermatology clinic every 4 weeks for 12 weeks.

Condition or Disease Intervention/Treatment Phase
  • Drug: Cassia alata extract
  • Drug: Placebo
Phase 1

Detailed Description

Tinea (pityriasis) versicolor is a common superficial fungal infection. A variety of topical antifungals are used in its treatment. In Jamaica, many people use crushed leaves of the Cassia alata plant (Senna alata) as a traditional remedy. Rare investigators have described its activity against the causative fungus, Malassezia spp. Aim: We wish to confirm the efficacy of the extract, devise dosing regimen, document potential side effects Study Design/Methodology: Prospective single-blinded (participant) two-arm (parallel) randomized placebo controlled pilot study examining for efficacy of a 100% Cassia alata extract to a placebo solution. Therapeutic efficacy reported as clinical and microbiological resolution of tinea versicolor will be assessed. Side effects and ease of use will be evaluated for and reported. Assessment will occur at baseline, 1 week, 4 weeks, 8 weeks and 12 weeks. Demographics will be tabulated and categorical variables generated. Associations of the presence/absence of these variables within both groups will be evaluated for using chi-squared tests. Results will be analyzed using SPSS version 23. Location: Dermatology Outpatient Clinic and/or Dermatology Ward Procedure Rooms at University Hospital of the West Indies. Data Storage: Unique study ID, locked room and password protected computer belonging to the principal investigator. Only approved study investigators will have access. Time frame: 12 months Confidentiality Statement: This study requires approval by the Ethics Committee, will require an informed consent and will comply with ethical rules governing research using human subjects, patient confidentiality and non-coercion as detailed within the proposal.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
A Single-blinded, Parallel-arm, Randomized Placebo-controlled Pilot Study Evaluating the Clinical Efficacy and Safety Profile of 100% Cassia Alata Extract Against Tinea Versicolor
Anticipated Study Start Date :
Feb 15, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

a solution consisting of alcohol base, green food colouring and glycerin

Drug: Placebo
1 ml placebo solution

Active Comparator: Treatment

Cassia alata extract

Drug: Cassia alata extract
1 ml Cassia alata extract

Outcome Measures

Primary Outcome Measures

  1. Lesion Clearance [12 weeks]

    Proportion of participants with no visible lesions on which treatment applied

  2. Fungal load [12 weeks]

    Change in the fungal load on skin scrapping

Secondary Outcome Measures

  1. painful skin reaction [12 weeks]

    Proportion of participants with painful lesion on which treatment applied

  2. Blistering skin lesion [12 weeks]

    Proportion of participants with blistering of lesion on which treatment applied

  3. Itching or Redness [12 weeks]

    Proportion of participants with icthing or redness of lesion on which treatment applied

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 18-89 of either sex

  • Clinical features suggestive of tinea versicolor AND Microscopic confirmation using skin scraping stains with chlorazol black preparation AND or Wood's lamp fluorescence

  • No treatment for versicolor in the preceding 4 weeks

  • No contraindications to the application of C.alata extract in solution including

  • No history of allergy to C. alata

  • No history of preservative allergy

  • No history of allergy to adhesives/tapes

Exclusion Criteria:
  • Age <18 or >89 years

  • Pregnant females

  • History of hypersensitivity to C. alata or preservative

  • Treatment within 4 weeks prior to enrollment

  • Lesions which do not meet the diagnostic criteria of tinea versicolor

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of the West Indies, Mona Kingston Other Jamaica 007

Sponsors and Collaborators

  • The University of The West Indies

Investigators

  • Principal Investigator: Johnathan Ho, MB BS Dr Sc, Univeristy of the West Indies

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
The University of The West Indies
ClinicalTrials.gov Identifier:
NCT05730244
Other Study ID Numbers:
  • CREC-MN.29, 2021/2022
First Posted:
Feb 15, 2023
Last Update Posted:
Feb 21, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The University of The West Indies
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2023